Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionClaritev Corporation Class A Common Stock (CTEV)
Fair value
Not available
ACCE price target
$24.40
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $23.50 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
43
out of 100
Analysts
80% buy
5 covering
1-year return
-64.6%
Dividend yield
0.00%
Claritev Corporation Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Claritev sells healthcare payment integrity and claims-cost software, the systems that flag billing errors and reprice claims for payers and providers. The business runs at a 73.0% gross margin and a 12.8% operating margin on 6.6% revenue growth, which is a reasonable profile for a data-driven services franchise, though the 404M market cap leaves it small and off every major index. The headline numbers look odd: a forward P/E of 3.4 against a trailing P/E of zero and a return on equity of -646.3% point to a highly levered balance sheet with negative book equity, so the earnings power sits behind a heavy debt load that a PM would need to see in the filings. The score of 45 out of 100 reflects that tension between cheap forward earnings and a capital structure that needs scrutiny. Worth a deeper look mainly to pressure-test the debt maturities and whether the forward earnings estimate survives contact with the cash flow statement.